NBP NovaBridge Biosciences
Financings ·
Pro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients.
The deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients.
The amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.
Nasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $62.9 million | $21.8 million |
| Net income (loss) | -$46.3 million | -$22.2 million |
| Cash and equivalents | $210.6 million | $68.3 million |
| Short-term investments | $210,000 | $105.1 million |
Our latest story on this, dated Aug 20, 2025: "I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering". The story links the filing or release it is based on. Read the story.
NovaBridge Biosciences trades under the ticker NBP on NASDAQ.
NovaBridge Biosciences is listed on NASDAQ.
The SEC Central Index Key (CIK) for NovaBridge Biosciences is 1778016. Its filings are on SEC EDGAR.
265,377,891 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-07.
Our directory records NovaBridge Biosciences under United States.
Our directory classifies NovaBridge Biosciences as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for NovaBridge Biosciences is US44975P1030.
aibio.space lists NovaBridge Biosciences among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
NovaBridge Biosciences reported a net loss of $46.3 million for the fiscal year ended Dec 31, 2025, per its annual report to the SEC.
$62.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
$210.8 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Our latest story on NovaBridge Biosciences, dated Aug 20, 2025: "I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering". Pro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients. Source.
From our story of Aug 20, 2025: The company says its existing cash and short-term investments, together with the net proceeds, will be sufficient to fund operating expenses and capital expenditures through the fourth quarter of 2028, including a randomized Phase 2 trial of givastomig. Source.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio